OncoMatch/Clinical Trials/NCT04956640
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Is NCT04956640 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for carcinoma, non-small-cell lung.
Treatment: LY3537982 · Pembrolizumab · Cetuximab · Pemetrexed · Cisplatin · Carboplatin — The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Endometrial Cancer
Ovarian Cancer
Pancreatic Cancer
Biomarker criteria
Required: KRAS g12c
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: oxaliplatin-containing regimen — advanced or metastatic CRC
participants must have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC
Must have received: irinotecan-containing regimen — advanced or metastatic CRC
participants must have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC
Cannot have received: KRAS G12C small molecule inhibitor
Exception: except in certain scenarios where such prior therapy is allowed as per protocol
Have received prior treatment with any KRAS G12C small molecule inhibitor, except in certain scenarios where such prior therapy is allowed as per protocol
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Have adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- USC Norris Cancer Hospital · Los Angeles, California
- Chao Family Comprehensive Cancer Ctr. · Orange, California
- Yale-New Haven Hospital · New Haven, Connecticut
- AdventHealth Orlando · Orlando, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify